Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis

Werner Rabitsch,Marija Bojic,Philipp Wohlfarth,Michael Leiner,Christian Schörgenhofer,Peter Kalhs,Axel Schulenburg,Christian Sillaber,Margit Mitterbauer,Wolfgang R. Sperr,Ulrich Jäger,K. Skrabs,Hildegard T. Greinix,Alexander Hermann,Wolfgang Lamm

Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis

2016

Werner Rabitsch
Marija Bojic
Philipp Wohlfarth
Michael Leiner
Christian Schörgenhofer
Peter Kalhs
Axel Schulenburg
Christian Sillaber
Margit Mitterbauer
Wolfgang R. Sperr
Ulrich Jäger
K. Skrabs
Hildegard T. Greinix
Alexander Hermann
Wolfgang Lamm

Purpose Treatment of refractory Hodgkin disease deserves specific considerations. Recently, alemtuzumab-BEAM has been introduced in allogeneic hematopoietic stem cell transplantation (HSCT) in these patients.

Keywords:

Etoposide
Refractory
Immunology
Hematopoietic stem cell transplantation
Refractory Hodgkin Lymphoma
Transplantation Conditioning
Alemtuzumab
Carmustine
Cytarabine
Biology
Single Center

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations